Form 4: Integra LifeSciences CFO Reports Stock Transactions

Integra LifeSciences EVP & CFO Lea Daniels Knight reported the acquisition of 111,179 restricted stock units and the disposition of 8,089 common shares for tax purposes.

Summary

• Lea Daniels Knight, Executive Vice President and Chief Financial Officer of Integra LifeSciences Holdings Corp (IART), reported transactions on March 11, 2026.
• Knight acquired 111,179 restricted stock units (RSUs) as part of an award.
• Knight disposed of 8,089 shares of common stock at a price of $9.61 per share to satisfy tax withholding obligations related to a vesting event.
• Following these transactions, Knight directly beneficially owns 50,489 shares of common stock and 111,179 restricted stock units.
• The restricted stock units are scheduled to vest over three years: 33% on the first anniversary, 33% on the second anniversary, and 34% on the third anniversary of the grant date of March 11, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive routine filing, reflecting ongoing executive compensation and retention efforts through equity awards, which aligns management incentives with long-term company performance.

Positives

• The grant of 111,179 restricted stock units to a key executive aligns management's long-term interests with shareholder value.

Negatives

• The disposition of 8,089 common shares, while a standard practice for tax withholding upon RSU vesting, reduces the executive's direct common stock ownership.

Future Outlook

The future outlook for the executive's equity compensation includes the vesting of 111,179 restricted stock units over a three-year period, with specific vesting percentages on the first, second, and third anniversaries of the March 11, 2026 grant date.

Industry Context

StockSavvy.ai notes that the grant of restricted stock units with a multi-year vesting schedule is a common practice in executive compensation across the medical technology and life sciences industries, aiming to incentivize long-term performance and retention.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as a component of executive compensation is a widely adopted practice, comparable to equity incentive programs at peer companies in the medical device sector such as Medtronic plc, Stryker Corporation, and Zimmer Biomet Holdings, Inc.
• Multi-year vesting schedules, like the 33%/33%/34% structure over three years, are standard mechanisms designed to align executive interests with sustained shareholder value creation and employee retention, consistent with global benchmarks for executive equity awards.

Stakeholder Impact

• Shareholders: The grant of RSUs aligns executive incentives with long-term shareholder value, potentially fostering sustained performance.
• Employees: This filing pertains to executive compensation and does not directly impact the broader employee base, though it reflects the company's compensation philosophy for key personnel.

Next Steps

• The restricted stock units will vest in three tranches: 33% on March 11, 2027, 33% on March 11, 2028, and 34% on March 11, 2029.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation transactions, specifically the grant of restricted stock units and the disposition of shares for tax purposes. Such transactions are standard and do not typically indicate a significant change in the company's fundamental outlook or warrant a strong buy or sell recommendation. Investors should view this as an expected part of executive incentive alignment.

Keywords

Integra LifeSciences, IART, Form 4, Insider Transaction, Restricted Stock Units, Executive Compensation, CFO, Equity Award